表紙
市場調査レポート

二次性副甲状腺機能亢進症:世界の治験レビュー

Secondary Hyperparathyroidism Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 305096
出版日 ページ情報 英文 108 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
二次性副甲状腺機能亢進症:世界の治験レビュー Secondary Hyperparathyroidism Global Clinical Trials Review, H1, 2014
出版日: 2014年05月30日 ページ情報: 英文 108 Pages
概要

当レポートでは、二次性副甲状腺機能亢進症に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤などの情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

  • 二次性副甲状腺機能亢進症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の上位5ヶ国
    • 欧州の上位5ヶ国
    • 北米の上位国
    • 中東・アフリカの上位国
    • 中南米の上位国

G7諸国での治験件数:代謝性疾患治験全体における二次性副甲状腺機能亢進症の割合

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:代謝性疾患治験全体における二次性副甲状腺機能亢進症の割合

E7諸国での治験件数:フェーズ(相)別

E7諸国での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • 二次性副甲状腺機能亢進症治療薬の治験に参加している上位企業

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概要
    • Amgen Inc
    • AbbVie Inc.
    • Sanofi
    • Abbott Laboratories
    • Cytochroma Inc.
    • OPKO Health, Inc.
    • Astellas Pharma Inc.
    • キリンホールディングス
    • Deltanoid Pharmaceuticals Inc.
    • T-cell Technologies, Inc.
  • 代表的な研究機関・病院の治験の概要
    • Centre Hospitalier Universitaire Vaudois
    • Atlanta VA Medical Center
    • University of California, Los Angeles
    • Creighton University
    • Roskilde County Hospital
    • Montefiore Medical Center
    • Indiana University School of Medicine
    • University of Washington
    • All India Institute of Medical Sciences
    • Weill Cornell Medical College

5つの代表的な治験のプロファイル

付録

図表一覧

目次
Product Code: GDHC2179CTIDB

GlobalData's clinical trial report, "Secondary Hyperparathyroidism Global Clinical Trials Review, H1, 2014" provides data on the Secondary Hyperparathyroidism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Secondary Hyperparathyroidism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Secondary Hyperparathyroidism. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Secondary Hyperparathyroidism
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Secondary Hyperparathyroidism to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Secondary Hyperparathyroidism to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Secondary Hyperparathyroidism
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Secondary Hyperparathyroidism Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Amgen Inc.
      • Clinical Trial Overview of Amgen Inc.
      • AbbVie Inc.
      • Clinical Trial Overview of AbbVie Inc.
      • Sanofi
      • Clinical Trial Overview of Sanofi
      • Abbott Laboratories
      • Clinical Trial Overview of Abbott Laboratories
      • Cytochroma Inc.
      • Clinical Trial Overview of Cytochroma Inc.
      • OPKO Health, Inc.
      • Clinical Trial Overview of OPKO Health, Inc.
      • Astellas Pharma Inc.
      • Clinical Trial Overview of Astellas Pharma Inc.
      • Kirin Holdings Company, Limited
      • Clinical Trial Overview of Kirin Holdings Company, Limited
      • Deltanoid Pharmaceuticals Inc.
      • Clinical Trial Overview of Deltanoid Pharmaceuticals Inc.
      • T-cell Technologies, Inc.
      • Clinical Trial Overview of T-cell Technologies, Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • Centre Hospitalier Universitaire Vaudois
      • Clinical Trial Overview of Centre Hospitalier Universitaire Vaudois
      • Atlanta VA Medical Center
      • Clinical Trial Overview of Atlanta VA Medical Center
      • University of California, Los Angeles
      • Clinical Trial Overview of University of California, Los Angeles
      • Creighton University
      • Clinical Trial Overview of Creighton University
      • Roskilde County Hospital
      • Clinical Trial Overview of Roskilde County Hospital
      • Montefiore Medical Center
      • Clinical Trial Overview of Montefiore Medical Center
      • Indiana University School of Medicine
      • Clinical Trial Overview of Indiana University School of Medicine
      • University of Washington
      • Clinical Trial Overview of University of Washington
      • All India Institute of Medical Sciences
      • Clinical Trial Overview of All India Institute of Medical Sciences
      • Weill Cornell Medical College
      • Clinical Trial Overview of Weill Cornell Medical College
    • Five Key Clinical Profiles
    • Appendix
      • Abbreviations
      • Definitions
      • Research Methodology
      • Secondary Research
      • About GlobalData
      • Contact Us
      • Disclaimer
      • Source

List of Tables

  • Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Region, 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Secondary Hyperparathyroidism to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014*
  • Secondary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Secondary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Secondary Hyperparathyroidism to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014*
  • Secondary Hyperparathyroidism Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Secondary Hyperparathyroidism Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Secondary Hyperparathyroidism Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytochroma Inc., 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by OPKO Health, Inc., 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Kirin Holdings Company, Limited, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Deltanoid Pharmaceuticals Inc., 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by T-cell Technologies, Inc., 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Centre Hospitalier Universitaire Vaudois, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Atlanta VA Medical Center, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Los Angeles, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Creighton University, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Roskilde County Hospital, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Montefiore Medical Center, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Indiana University School of Medicine, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by All India Institute of Medical Sciences, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Weill Cornell Medical College, 2014*

List of Figures

  • Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
  • Proportion of Secondary Hyperparathyroidism to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014*
  • Secondary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Secondary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Secondary Hyperparathyroidism to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014*
  • Secondary Hyperparathyroidism Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Secondary Hyperparathyroidism Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Secondary Hyperparathyroidism Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top